Janssen Research & Development LLC, a Johnson & Johnson company GARDENIA-SLE

Other News

Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, is encouraged by positive late-breaking Phase 2 data with nipocalimab, an investigational drug in development by Johnson...

Positive Results of Phase 3 Dapirolizumab Pegol Trial in Systemic Lupus Erythematosus Shown in Published Paper

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, welcomes additional positive results from the Phase 3 PHOENYCS GO study showing...

2026 LuCIN Community Meeting Focuses on Integrating Clinical Trials into Day-to-Day Clinical Care

What if clinical trials were not a final option, but a routine part of lupus care? That question took center stage...